MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Despite being the most widely used drug in the US, Humira, known for its effectiveness ... plaque psoriasis, and hidradenitis suppurativa. RxPreferred is the second PBM to offer Yusimry.

Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis, and hidradenitis suppurativa.

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

This guide offers practical strategies to navigate the challenges of summer, aiming to keep HS at bay and during the hottest ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

Genetic research, single-cell RNA sequencing, and spatial transcriptomics suggest that a prolonged anagen stage in the ...

Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health ...

A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

Patients with hidradenitis suppurative seek advice online, highlighting unmet needs in clinician-patient education regarding ...

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship ...